EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Nanoparticle-Based Dry Powder Inhaler Containing Ciprofloxacin for Enhanced Targeted Antibacterial Therapy

Petra Party iD, Márk László Klement, Bianca Maria Gaudio, Milena Sorrenti iD, Rita Ambrus iD

Pharmaceutics · 07.04.2025 · 17 (4) · 486

DOI: 10.3390/pharmaceutics17040486 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 07.04.2025. Verfasst von Petra Party und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, 6720 Szeged, Hungary. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Szeged Open Access Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ciprofloxacin (CIP) is a poorly water-soluble fluoroquinolone-type antibiotic that can be useful in the treatment of lung infections. When the drugs are delivered directly to the lungs, a smaller dosage is needed to achieve the desired effect compared to the oral administration. Moreover, the application of nanoparticles potentially enhances the effectiveness of the treatments while lowering the possible side effects. Therefore, we aimed to develop a “nano-in-micro” structured dry powder inhaler formulation containing CIP.

Methods

A two-step preparation method was used. Firstly, a nanosuspension was first prepared using a high-performance planetary mill by wet milling. After the addition of different additives (leucine and mannitol), the solid formulations were created by spray drying. The prepared DPI samples were analyzed by using laser diffraction, nanoparticle tracking analysis, scanning electron microscopy, X-ray powder diffraction, and differential scanning calorimetry. The solubility and in vitro dissolution tests in artificial lung fluid and in vitro aerodynamic investigations (Spraytec® device, Andersen Cascade Impactor) were carried out.

Results

The nanosuspension (D50: 140.0 ± 12.8 nm) was successfully prepared by the particle size reduction method. The DPIs were suitable for inhalation based on the particle diameter and their spherical shape. Improved surface area and amorphization after the preparation processes led to faster drug release. The excipient-containing systems were characterized by large lung deposition (fine particle fraction around 40%) and suitable aerodynamic diameter (between 3 and 4 µm).

Conclusions

We have successfully formulated a nanosized antibiotic-containing formulation for pulmonary delivery, which could provide a potential treatment for patients with different respiratory infections.

Schlagwörter

Stichwörter der Autor:innen

aerodynamic characterizationciprofloxacindry powder inhalernanosuspensionspray dryingwet milling

Autor:innen und Institutionen

  • Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, 6720 Szeged, Hungary.
  • Department of Drug Sciences, University of Pavia, 27100 Pavia, Italy.

ORCID-Profile: Petra Party, Milena Sorrenti, Rita Ambrus

Förderung

  • University of Szeged Open Access Fund

Zitieren

APA

Party, P., Klement, M. L., Gaudio, B. M., Sorrenti, M., & Ambrus, R. (2025). Nanoparticle-Based Dry Powder Inhaler Containing Ciprofloxacin for Enhanced Targeted Antibacterial Therapy. Pharmaceutics, 17(4), 486. https://doi.org/10.3390/pharmaceutics17040486

Vancouver

Party P, Klement ML, Gaudio BM, Sorrenti M, Ambrus R. Nanoparticle-Based Dry Powder Inhaler Containing Ciprofloxacin for Enhanced Targeted Antibacterial Therapy. Pharmaceutics. 2025;17(4):486. doi:10.3390/pharmaceutics17040486

BibTeX
@article{Party2025,
  author = {Party, Petra and Klement, Márk László and Gaudio, Bianca Maria and Sorrenti, Milena and Ambrus, Rita},
  title = {Nanoparticle-Based Dry Powder Inhaler Containing Ciprofloxacin for Enhanced Targeted Antibacterial Therapy},
  journal = {Pharmaceutics},
  year = {2025},
  volume = {17},
  number = {4},
  pages = {486},
  doi = {10.3390/pharmaceutics17040486}
}
Kostenlos starten →